

MEDICAL PROPERTIES TRUST INC  
Form 8-K  
December 31, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**  
**Date of Report (Date of earliest event reported): December 31, 2018**

**MEDICAL PROPERTIES TRUST, INC.**  
**(Exact Name of Registrant as Specified in Charter)**

**Commission File Number 001-32559**

**Maryland**  
**(State or other jurisdiction of**  
**incorporation or organization )**

**20-0191742**  
**(I. R. S. Employer**  
**Identification No.)**

**1000 Urban Center Drive, Suite 501**

**Birmingham, AL**  
**(Address of principal executive offices)**

**35242**  
**(Zip Code)**

**(205) 969-3755**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01. Other Events.**

On December 31, 2018, Medical Properties Trust, Inc. (the Company) filed a new prospectus supplement with the Securities and Exchange Commission (the SEC) with respect to the Company's existing \$750,000,000 at-the-market equity offering program (the ATM Program). The new prospectus supplement was filed as a result of the Company's filing with the SEC on December 31, 2018 of a new shelf registration statement on Form S-3 (File No. 333-229103), which replaced the Company's previously filed shelf registration statement on Form S-3.

On December 31, 2018, the Company entered into amendments to its Equity Distribution Agreements, each dated as of November 13, 2017, with each of SunTrust Robinson Humphrey, Inc., Credit Agricole Securities (USA) Inc., Credit Suisse Securities (USA) LLC, MUFG Securities Americas Inc., Raymond James & Associates, Inc., RBC Capital Markets, LLC, Stifel, Nicolaus & Company, Incorporated and Wells Fargo Securities, LLC, as sales agents, which provide, among other matters, that any offers and sales of shares of the Company's common stock under the ATM Program will be made pursuant to the new prospectus supplement.

In connection with the Company's filing with the SEC of the new prospectus supplement with respect to the existing ATM Program, the Company is filing certain exhibits as part of this Current Report on Form 8-K. See Item 9.01. Financial Statements and Exhibits.

This Current Report shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

**Exhibit**

<b>No.</b>	<b>Description</b>
5.1	<u>Opinion of Goodwin Procter LLP regarding the legality of shares offered</u>
8.1	<u>Opinion of Baker, Donelson, Bearman, Caldwell &amp; Berkowitz, P.C. with respect to certain tax matters</u>
23.1	<u>Consent of Goodwin Procter LLP (included in Exhibit 5.1)</u>
23.2	<u>Consent of Baker, Donelson, Bearman, Caldwell &amp; Berkowitz, P.C. (included in Exhibit 8.1)</u>

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunder duly authorized.

**MEDICAL PROPERTIES TRUST, INC.**

By: /s/ R. Steven Hamner  
Name: R. Steven Hamner  
Title: Executive Vice President and Chief  
Financial Officer

Date: December 31, 2018